Endoscopic Treatment of GERD (L30473)
Contractor Information
|
Contractor Name Wisconsin Physicians Service Insurance Corporation |
Contractor Number 00951, 00952, 00953, 00954, 52280, 05101, 05201, 05301, 05401, 05102, 05202, 05302, 05402 |
Contractor Type Carrier - FI - MAC |
LCD Information
L30473 LCD Title Endoscopic Treatment of GERD Contractor's Determination Number GI-010 AMA CPT/ADA CDT Copyright Statement CPT codes, descriptions and other data only are copyright 2010 American Medical Association (or such other date of publication of CPT). All Rights Reserved. Applicable FARS/DFARS Clauses Apply. Current Dental Terminology, (CDT) (including procedure codes, nomenclature, descriptors and other data contained therein) is copyright by the American Dental Association. © 2002, 2004 American Dental Association. All rights reserved. Applicable FARS/DFARS apply. |
Primary Geographic Jurisdiction
Oversight Region Original Determination Effective Date For services performed on or after 04/15/2010 Original Determination Ending Date Revision Effective Date For services performed on or after 03/01/2012 Revision Ending Date |
Title XVIII of the Social Security Act, Section 1833(e). This section prohibits Medicare payment for any claim which lacks the necessary information to process the claim.
Currently, these procedures are considered non-covered due to the fact that current peer-reviewed literature does not support the efficacy of the services. Claims will be denied as "not proven effective."
The Stretta ® procedure is an endoluminal treatment for GERD in which radiofrequency energy is delivered to smooth muscle of the lower esophageal sphincter (LES). A flexible catheter equipped with special needle electrodes for precise energy delivery is placed by mouth into the esophagus and carefully controlled radiofrequency energy is then delivered to the LES and gastric cardia, creating thermal lesions. The manufacturer maintains that the changes that occur immediately, and over time, result in a "tighter" LES and a less compliant gastric cardia. Additionally, the interruption of nerve pathways in the LES area is believed to reduce the incidence of inappropriate LES "relaxations," leading to an improvement in GERD symptoms. Substantial peer-reviewed evidence to fully support these assumptions remains to be published.
The Bard EndoCinch Suturing System and the Plicator are intended for use in endoscopic placement of suture(s) in the soft tissue of the esophagus and stomach and for approximation of tissue for treatment of symptomatic gastroesophageal reflux disease.
EsophyX is a device for performing transoral incisionless fundoplication surgery for treating gastroesophageal reflux disease. This procedure reconstructs the valve at the top of the stomach that helps prevents acid reflux.
Enteryx ® is an endoscopic, minimally-invasive procedure in which an ethylene vinyl alcohol polymer solution is injected into your lower esophageal sphincter muscle using a small needle. This product was recalled in September 2005 due to adverse patient events.
These procedures are promising for treatment of patients in whom proton pump inhibitor therapy fails. Clinical data from various studies are emerging. At this time, open-label studies or patient registries with short term follow-ups are the dominant source of data. The overwhelming preponderance of reviewers remain equivocal in their support and have called for randomized controlled trials with long-term follow-ups. In the absence of evidence from such studies, and in the absence of wide acceptance, endoscopic treatments for GERD are not proven effective. Therefore, they are not reimbursable even though some of the treatments may have associated CPT or OPPS codes.
Coding Information
Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims.
Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory; unless specified in the policy services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.
| 43257 | UPPER GASTROINTESTINAL ENDOSCOPY INCLUDING ESOPHAGUS, STOMACH, AND EITHER THE DUODENUM AND/OR JEJUNUM AS APPROPRIATE; WITH DELIVERY OF THERMAL ENERGY TO THE MUSCLE OF LOWER ESOPHAGEAL SPHINCTER AND/OR GASTRIC CARDIA, FOR TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE |
| 43499 | UNLISTED PROCEDURE, ESOPHAGUS |
| 43999 | UNLISTED PROCEDURE, STOMACH |
| 49999 | UNLISTED PROCEDURE, ABDOMEN, PERITONEUM AND OMENTUM |
| C9724 | ENDOSCOPIC FULL-THICKNESS PLICATION IN THE GASTRIC CARDIA USING ENDOSCOPIC PLICATION SYSTEM (EPS); INCLUDES ENDOSCOPY |
ICD-9 Codes that Support Medical Necessity
NA
| XX000 | Not Applicable |
Diagnoses that Support Medical Necessity
NA
ICD-9 Codes that DO NOT Support Medical Necessity
ICD-9 Codes that DO NOT Support Medical Necessity Asterisk Explanation
Diagnoses that DO NOT Support Medical Necessity
General Information
Appendices
Utilization Guidelines
Sources of Information and Basis for Decision
2. Jafri Sm et al, What is left of the endoscopic antireflux devices? Current Opinion Gastroenterology 2009 July 25(4): 352-7
3. Medical Letter Volume 6 (Issue 72) August 2008, Treatment of Peptic Ulcers and GERD
4. Other Medicare Contractor Local Coverage Determinations and article of coverage
5. Alessandro Repici et.al, Endoluminal Fundoplication (ELF) for GERD Using EsophyX: a 12-Month Follow-up in a Single-Center Experience; J Gastrointest Surg (2010) 14:1 6
6. Guy-Bernard Cadie're et. al, Two-year results of a feasibility study on antireflux transoral incisionless fundoplication using EsophyX, Surg Endosc Received: 12 June 2008 / Accepted: 12 January 2009
7. Triadafilopoulos G, DiBaise JK, Nostrant TT, Stollman NH, Anderson PK, Wolfe MM, Rothstein RI, WO JM, Corley DA, Patti MG, Antignano LV, Goff JS, Edmundowicz SA, Castell DO, Rabine JC, Kim MS, Utley DS. The STRETTA procedure for the treatment of GERD: 6 and 12-month follow-up of the U.S. open label trial. Gastrointestinal Endoscopy 2002 Feb; 55 (2): 149-156
8. Hogan, Walter J MD; ASGE leadership: Promoting or validating endoscopic technology?; Gastrointestinal Endoscopy Vol 60 No 2 August 2004
9. Blue Cross Blue Shield Association Technology Evaluation Center; Transesophageal Endoscopic Treatments for Gastroesophageal Disease Assessment Program; Vol 18 No 20 Feb 2004
10. Kahrilas, Peter J MD; Technology Review: Radiofrequency therapy of the lower esophageal sphincter for treatment of GERD; Gastrointestinal Endoscopy Vol 57 No 6 May 2003
11. Hogan, Walter J MD, Shaker, Reza MD; A Critical review of endoscopic therapy for gastroesophageal reflux disease; Am J Med Vol 115 No 3 August 18, 2003
12. Metz, David C MD; Managing gastroesophageal reflux disease for the lifetime of the patient: Evaluating the long-term options; Am J of Med Supplements Vol 117 No 5A September 6, 2004
13. William O. Richards, M.D., F.A.C.S.; Gastroesophageal Reflux Disease and the Truth About Endoluminal Therapy
14. Go, Dundon, et. al.; Delivery of radiofrequency energy to the lower esophageal sphincter improves symptoms of gastroesophageal reflux; Surgery, Vol 136 No 4 October 2004
15. George Triadafilopoulos, M.D.; Stretta: An Effective, Minimally Invasive Treatment of Gastroesophageal Reflux Disease; The Am J. of Med. Vol 115, August 18, 2003
16. Wolfson & Richards; The Stretta Procedure for the Treatment of GERD: A Registry of 558 patients; Journal of Laparoendoscopic & Advanced Surgical Techniques, Vol 12 No 6 2002
17. Cohen et al; Enteryx Implantation for GERD: Expanded multicenter Trial Results and Interim Postapproval Follow-Up to 24 months; Gastrointestinal Endoscopy, Vol 61 no 6: May 2005
Advisory Committee Meeting Notes
Wisconsin 9/25/09
Illinois 9/16/09
Michigan 9/09/09
Minnesota 09/24/09
J5 MAC 10/08/09
Open Meeting Date 08/19/2009
Notes
This policy does not reflect the sole opinion of the contractor or Contractor Medical Director. Although the final decision rests with the MAC contractor this policy was developed in cooperation with advisory groups which include representatives from various specialties, and adapted for the purpose of converting to MAC jurisdiction.
Start Date of Comment Period
Revision History Explanation
10/18/2010 - In accordance with Section 911 of the Medicare Modernization Act of 2003, the states of Colorado, New Mexico, Oklahoma and Texas were removed from this LCD because claims processing for those states are transitioning from FI Wisconsin Physicians Service (52280) to MAC Part A Trailblazer (04901).
02/21/2011 In accordance with Section 911 of the Medicare Modernization Act of 2003, the states of Delaware, District of Columbia, Maryland, New Jersey and Pennsylvania were removed from this LCD because claims processing for these states are transitioning from FI Wisconsin Physician Service (WPS 52280) to MAC Part A contractor Highmark (12901).
04/01/2011- Annual review- no change to coverage.
03/01/2012- Annual Review, no change to coverage;
Reason for Change
Related Documents
LCD Attachments
NOTE: Should you have landed here as a result of a search engine (or other) link, be advised that these files contain material that is copyrighted by the American Medical Association. You are forbidden to download the files unless you read, agree to, and abide by the provisions of the copyright statement. Read the copyright statement now.
Page Last Updated: Thursday, 01-Mar-2012 14:11:32 CST
